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Brain tumors display extensive diversity. In this issue ofCancer Cell, Swartling et al. provide evidence that the
temporal and spatial transcriptional programs in neural stem cells underlie a diverse response to the MYCN
oncogene, potentially contributing to cancer diversity.The billions of neurons and glia that form
the central nervous system (CNS) arise
from neural stem cells (NSCs) derived
from the neural tube (Kriegstein and
Alvarez-Buylla, 2009). Throughout devel-
opment, the daughters of NSCs follow
topographically and temporally discrete
cellular programs; spinal neurons are
distinct from those that form in the cortex,
and neurogenesis precedes gliogenesis
in the forebrain. These programs are con-
trolled by a combination of cell intrinsic
and extrinsic factors e.g., chromatin
marks and morphogens (Gra¨ff et al.,
2011; Ihrie and Alvarez-Buylla, 2011).
Recent evidence suggests that highly
specific developmental programs might
render cells peculiarly susceptible to
particular oncogenic events, resulting in
the formation of discrete subgroups of
cancer (Gilbertson, 2011). For example,
robust subgroups of the brain tumors
ependymoma and medulloblastoma con-
tain global gene expression profiles that
reflect their developmental and molecular
origins in the CNS (Gibson et al., 2010;
Johnson et al., 2010; Kawauchi et al.,
2012; Pei et al., 2012).
In this issue of Cancer Cell, Swartling
et al. (2012) investigate how different
mouse NSC populations respond to aber-
rant expression of MYCN—an oncogene
commonly deregulated in various human
brain tumors. Through a series of elegant
in vitro and in vivo studies, the authors
challenged cells from different regions of
the developing CNS with wild-type or
mutant MYCN. They show that distinct
populations of NSCs display different
cellular response to this oncogene,
including transformation capacity, and
ultimately the type of tumor produced
(Figure 1).
First, using their previously reported
GTML mouse model of MYCN-drivenmedulloblastoma (Swartling et al., 2010),
the authors show that MYCN drives Sonic
Hedgehog (SHH) independent prolifera-
tion of GTML cells and that tumor growth
likely correlates withMYCN expression in
these tumors. Switching to the developing
CNS, the authors then surveyed potential
susceptibility to N-myc driven transfor-
mation by assessing the response of
NSCs from different neurogenic regions
to wild-type (N-MycWT) or stabilized
mutant N-MycT58A. N-MycT58A, but not
N-MycWT, significantly increased the
proliferation of cerebellar and forebrain
NSCs isolated from either embryonic
day 16 (E16) or postnatal day 0 (P0)
mice. In contrast, E14 rather than E16
lower rhombic lip progenitors (LRLPs),
proliferated in response to N-MycT58A;
confirming previous reports that these
cells are susceptible to transformation
early in development (Gibson et al.,
2010) and revealing temporal differences
in susceptibility to N-Myc.
In addition to inducing proliferation,
N-MycT58A also appeared to subvert
intrinsic cell signals in certain NSCs.
Once again, this effect varied with the
time and the place from which NSCs
were isolated. Prompted by changes in
Sox9 expression that acts downstream
of SHH signaling in NSCs (Scott et al.,
2010), the authors noted that while
N-MycT58A promoted SHH-independence
in E16 cerebellar and P0 forebrain cells,
this did not appear to occur in P0 cere-
bellar and E16 forebrain cells.
Armed with these data, the authors
asked whether cell context might dictate
the capacity of N-MycWT or N-MycT58A to
drive tumorigenesis in theCNS. In keeping
with their observations in vitro, N-MycWT-
transduced NSCs failed to form tumors
when orthotopically implanted in mice.
But N-MycT58A drove transformation ofCancer CelE16 and P0 cerebellar and forebrain
NSCs as well as E14, but not E16 or P0,
LRLPs. Interestingly, N-MycT58A-trans-
duced P0 cerebellar NSCs formed tumors
in the cerebellum that resembled human
and mouse GTML medulloblastoma,
while N-MycT58A-transduced P0 forebrain
NSCs generated gliomas in the cerebrum.
To clarify the influence of intrinsic versus
extrinsic factors on the type of brain tumor
formed in these models, the authors
transplanted P0 forebrain and cerebellar
NSCs, each transduced with N-MycT58A,
into the cerebellum and forebrain, respec-
tively. Their results suggest that the cell of
origin plays a dominant role in determining
tumor phenotype, as forebrain cells still
made gliomas in the cerebellum, and
cerebellar cellsmade primitive neuroecto-
dermal tumors in the forebrain. The only
difference noted was a modest reciprocal
change in Sox9 and Olig2 within ‘‘mis-
placed’’ tumor implants. So while pro-
grams intrinsic to particular NSCs may
primarily determine the course of
tumorigenesis, a role for environmental
influence in tumor specification remains
a possibility.
Together, these data support a growing
body of evidence that the cellular origin
of cancers heavily dictates disease
phenotype and biology and that this
lineage relationship is often revealed
by a cancer’s transcriptome (Gilbertson,
2011). Indeed, using Affymetrix exon
arrays, Swartling et al. (2012) identified a
close alignment between the gene
expression patterns of N-MycT58A tumors
and the corresponding, originating, cere-
bellar or forebrain NSC. In an additional
twist on this theme, the authors showed
that NSCs derived from different devel-
opmental stages of the cerebellum
generate distinct forms of medulloblas-
toma. Medulloblastomas derived froml 21, May 15, 2012 ª2012 Elsevier Inc. 593
Figure 1. There Is a Time and a Place for N-Myc-Driven Tumorigenesis in the CNS
Swartling et al. (2012) show that different NSCs in the mouse CNS are differentially susceptible to transformation by N-Myc, driving time and location-specific
tumors.
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of Sox9, Mycn, and the granule neuron
precursor marker Math1, suggesting a
Shh-dependent form of the disease.
In contrast, medulloblastomas derived
from P0 cells displayed lower expression
of Sox9, Mycn, and Math1 compatible
with a SHH-independent origin. Forebrain
N-MycT58A P0 tumors (P0 glioma)
also showed high levels of Sox9 and
Mycn with no Math1, consistent with
transformation of a forebrain cell type
that shows Shh-dependence indepen-
dently of Math1.
Finally, the authors used their model
systems to begin to unravel some of the
cell signals that drive tumorigenesis in
concert with N-Myc. Focusing on Sox9,
the authors investigated whether this
putative effector of SHH signaling plays
a functional role in transforming P0 cere-
bellar NSCs. Overexpression of Sox9
with N-MycT58A in P0 cerebellar NSCs
suppressed proliferation but enhanced
self-renewal, ultimately causing tumors
to arise with shorter latencies and higher
penetrance. Tumors driven by Sox9 with
N-MycT58A also showed elevated levels
of Gli2, and focal expression of GFAP,
not seen in those driven by N-MycT58A
alone. These studies reveal potential594 Cancer Cell 21, May 15, 2012 ª2012 Elscooperative interactions between N-Myc
and Sox9 in the development of brain
tumor subtypes.
This work by Swartling et al. (2012)
represents an important step forward in
understanding the mechanisms that
contribute to tumor diversity in the CNS.
Using a single oncogene, MYCN, the
authors were able to generate different
types of CNS tumor by varying the age
and location of the originating NSC. These
data not only confirm a role for MYCN in
forebrain and hindbrain tumorigenesis
but also underscore the emerging impor-
tance of the originating cell type in
dictating the cancer phenotype. The
observation that N-MycT58A drives
anaplastic medulloblastomas from E14
LRLPs independent of WNT signaling is
noteworthy, because these same cells
were shown to generate WNT-subgroup
medulloblastomas (Gibson et al., 2010).
Thus, LRLPs that reside outside the
cerebellum might be a source of multiple
forms of medulloblastoma. Comparison
of Swartling’s MYCN-driven model with
recently reported tumors driven by MYC
should also help unravel the different
roles of these ‘‘sister’’ oncogenes in
medulloblastoma (Kawauchi et al., 2012;
Pei et al., 2012). The authors note appro-evier Inc.priately that the originating cell types in
their models are yet to be defined formally
as NSCs, but this does not detract
from the importance of their work that
demonstrates time and location specific
tumorigenesis in the CNS. The data and
models generated by Swartling et al.
(2012) should provide an extremely useful
resource to the brain tumor research
community as we seek to unravel the
diversity of these diseases and develop
curative therapies for all patients.
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In this issue of Cancer Cell, Gannon and colleagues create genetically engineered mice to test the role phos-
phorylation plays in the modification of one serine long thought to play a critical role in controlling the activity
of MDM2, one of p53’s main negative regulators.The tumor suppressor p53 is activated
by numerous stressors and results in
expression or repression of hundreds of
genes that elicit a broad range of biolog-
ical responses culminating in effective
tumor suppression. However, p53 acti-
vation must be controlled with exquisite
care because as little as a 2-fold reduc-
tion in its activity can cause radio resis-
tance and increased tumorigenicity
(Bondet al., 2004;Wanget al., 2009). Con-
versely, a 2-fold increase in p53 activity
such as in p537KR/7KR mice (a knock-
in model in which seven conserved
C-terminal lysine residues were replaced
by arginine) can lead to myeloblation and
death by heart failure (Wang et al., 2011).
Ubiquitin-mediated proteolysis is cen-
tral to controlling p53’s protein level
and activity. In unstressed cells, the
E3 ubiquitin-ligase MDM2 recruits E2
ubiquitin-conjugating enzymes to trans-
fer ubiquitins onto p53 and MDM2 itself,
resulting in proteasomal degradation of
both proteins. MDM4 (also known as
MDMX), a protein related to MDM2 but
lacking intrinsic E3 ubiquitin-ligase
activity, hetero-oligomerizes with MDM2
to modulate MDM20s E3 ligase activity
(Wade et al., 2010). MDM2 and MDM4
play non-overlapping and tissue-specific
roles to precisely control p53 levels and
activity (Wade et al., 2010). DeletingMdm2 typically elicits a more extreme
phenotype than deleting Mdm4, but
eliminating p53 rescues both. This
demonstrates that both MDM2 and
MDM4 are critical nodes in p53 regula-
tion. MDM2 is a p53-induced gene, and
in vitro studies show that increasing
MDM2 abundance can attenuate p53
activation, leading p53 to return to low
basal levels upon resolution of the
inducing stress. The importance of this
negative feedback loop for p53 regulation
in vivo in different tissues remains unclear.
Correct temporal control of p53
responses is critical, but how this is
achieved in vivo remains to be resolved.
Posttranslational modifications play crit-
ical roles in p53 regulation, so the
residues of p53, MDM2, and MDM4
that are modified by damage-activated
kinases, phosphatases, and other modi-
fying enzymes are prime candidates
for temporal regulators. The acceptable
thresholds for p53 regulation have been
dramatically revealed by studies showing
that mice heterozygous for Mdm2 or
Mdm4, with reduced expression of
Mdm2 or Mdm4, or with blocked post-
translational modification at damage-
modifiable residues have profoundly
altered radiation responses (Bondar and
Medzhitov, 2010; Wang et al., 2009).
Ionizing radiation activates DNAdamage-activated kinases such as ATM
and CHK2, resulting in phosphorylation
of multiple residues on MDM2, MDM4,
and p53 (Wade et al., 2010). Studies in
human cancer cell lines first suggested
that preventing MDM2 Ser395 (mouse
Ser394) phosphorylation could impair its
damage-dependent degradation and
consequently attenuate p53 activation
(Maya et al., 2001). DNA damage also
induces MDM4 phosphorylation at serine
341,367, and 402, resulting in its MDM2-
dependent degradation. Mice expressing
Mdm4 3SA, anMDM4mutant with alanine
substitutions at these three positions, are
remarkably resistant to ionizing radiation
due to attenuated radiation-induced p53
responses in the hematopoietic system
but are very sensitive to c-Myc induced
lymphomagenesis (Wang et al., 2009).
Both phenotypes result from a modest
2-fold reduction in p53 basal and induced
activity. These data suggest the impor-
tance of regulating MDM4 stability in vivo
for controlling p53 activity.
In this issue of Cancer Cell, Gannon
et al. (2012) demonstrate the importance
of MDM2 Ser394 phosphorylation in
regulating the responses of mice to
irradiation by making S394A (non-phos-
phorylatable) and S394D (phosphomi-
metic) mutations. They show that this
amino acid can swing the penduluml 21, May 15, 2012 ª2012 Elsevier Inc. 595
